As ILC risk is close to the overall breast cancer risk seen in carriers of BRCA1/BRCA2 mutations, it seems reasonable to offer the same type of surveillance as a routine procedure, and start screening at age 30 years with annual MRI and mammogram [104,105]. This evidence concerns the gene BRCA1 and breast carcinoma.